Fig. 2

Antiviral activities of Aspergillipeptide D against HSV-1 and ACV-resistant strains. Plaque reduction assay was used to evaluate the antiviral activity of Aspergillipeptide D against HSV-1/F, a standard experimental strains (a); HSV-1/blue, a TK mutant derived from HSV-1 (KOS) (c); HSV-1/106 and HSV-1/153, two ACV-resistant clinical HSV-1 strains, respectively (b, d). Vero cells were infected with HSV-1, HSV-1/153, HSV-1/Blue and HSV-1/106 (MOI = 0.1) at 37 °C for 2 h. The supernatant was then discarded, and the cover fluid containing with Aspergillipeptide D was added. After 72 h, the cells were fixed, dyed, and the plaque inhibition rate was calculated. Data are mean ± SD (n = 3)